Ask Onix
Surge in weight-loss drug use alters consumer behavior
Approximately 1.6 million people in the UK used weight-loss injections in 2024, with millions more expressing interest, according to University College London research. These drugs, which mimic the hormone GLP-1 to suppress appetite, are not only changing waistlines but also transforming how users spend their money.
Food industry adapts to smaller, healthier portions
Supermarkets and food retailers are responding to shifting consumer habits. Chains like The Co-op, Morrisons, and Marks & Spencer have introduced nutrient-dense ready meals, while Ocado now offers a 100g steak, citing demand for smaller portions. Sam Gillson, 38, from Shropshire, who has lost over four stone since June, noted his grocery bills have decreased as he buys fewer processed foods like pizza and chips, opting instead for fresh, nutrient-rich options.
"The smaller quantity needs to contain all the nutrients and vitamins you need," Gillson said.
Dining out and alcohol consumption decline
A KAM Insight survey found nearly a third of GLP-1 users dine out less frequently. Annie Haslam, 70, from Cornwall, who spends £186 monthly on injections, has cut takeaways and restaurant visits entirely. Similarly, a February 2025 study by Worldpanel by Numerator revealed a 15-percentage-point drop in alcohol purchases among households using these drugs. Nicole Tallant of The Co-op noted users are prioritizing overall health, reducing both food and alcohol intake.
Jonny Forsyth of Mintel warned alcohol companies could face challenges as GLP-1 drugs amplify existing trends toward sobriety. The British Beer and Pub Association expects a record 200 million pints of low- or no-alcohol beer to be consumed in 2025.
Fashion and beauty sectors see mixed impact
Rapid weight loss has led to increased spending on clothing. Haslam, who dropped from a size 18 to a size 12, estimated she spent "a couple of thousand pounds" replacing her wardrobe. Dan Coatsworth of AJ Bell suggested the trend could boost fashion retailers, particularly second-hand platforms like Vinted, as users quickly outgrow their clothes.
Simone Konu-Rae of Central Saint Martins noted users may seek a "reinvention" through fashion, exploring styles previously inaccessible. Meanwhile, the beauty sector has yet to launch UK products specifically for GLP-1 users, though US brands offer niche, high-cost options. Georgia Stafford of Mintel observed that existing anti-aging products, promising plumper skin and fuller hair, may already appeal to this demographic.
Fitness and wellness industries capitalize on demand
The Gym Group CEO Will Orr reported increased demand for fitness services as users aim to maintain weight loss and build muscle. The company is training staff to support members on GLP-1 treatments. Wellness retreats targeting drug users are emerging in the UK, following a US trend.
The British Association of Aesthetic Plastic Surgeons reported an 8% rise in facelift demand in 2024, linking it to post-weight-loss patients, a pattern amplified by GLP-1 medications.
Costs and trade-offs
While users like Gillson spend less on food, the £300+ monthly cost of private injections often offsets savings. Haslam, who allocates £186 monthly, has reduced discretionary spending elsewhere. Stafford noted that high drug costs might lead users to cut back in other areas, despite increased spending on healthcare and supplements.
